ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
June 20 2024 - 5:00AM
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its
Next Stage of Growth
- With a significant track record of success in the
radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s
pipeline and business growth
Garching / Munich, Germany, June 20,
2024 – ITM Isotope Technologies Munich SE (ITM), a leading
radiopharmaceutical biotech company today announced the appointment
of Dr. Andrew Cavey, as its Chief Executive Officer effective
September 1, 2024. ITM’s current CEO, Steffen Schuster, will step
up to the company’s Supervisory Board.“The strength of ITM is our
ability to deliver radiopharmaceutical innovation. With his strong
global background in clinical practice, strategy, clinical
development, and commercialization, we are confident that Andrew is
the right choice to lead ITM throughout our next growth phase,”
said Udo J. Vetter, Chairman of the Supervisory Board of
ITM. “I would like to thank Steffen for his dedication and
leadership over the last twelve years. His impact on the company’s
growth and development cannot be understated. I am delighted that
we will continue to benefit from his expertise and I welcome him to
the Supervisory Board.”Dr. Cavey will work together with ITM’s
leadership team to spearhead the next stages of growth as the
company broadens and advances its targeted radiopharmaceutical
pipeline and expands its industry-leading medical radioisotope
manufacturing capabilities. He joins ITM with a career spanning
clinical development, corporate strategy and commercial management
across international biotech and radiopharmaceutical companies
including Bristol Myers Squibb (BMS) and Novartis.“The ITM team has
created an impressive organization. Today the company is a
cornerstone of the radiopharmaceutical industry, with its supply of
high-quality medical radioisotopes and its broad pipeline of
innovative radiopharmaceutical medicines across cancer indications,
including its lead program ITM-11 in the final stages of
development,” said Dr. Andrew Cavey, “and I look
forward to working with the entire ITM team to deliver on the
company’s exceptional potential.”Dr. Cavey will join ITM from his
most recent position as SVP, Head of Global Program Leaders,
Hematology, Oncology, Cell Therapy at BMS, where he helped the
company enter into radiopharmaceuticals. Before this, he held
several leadership positions at Novartis over the course of eleven
years, culminating in his role as Global Program Head, Prostate
Cancer, in which he co-led the company’s Radiopharmaceutical
Therapy strategy and led teams overseeing the regulatory approvals
of Pluvicto® and Locametz® in the US and Europe. Dr. Cavey holds
his physiological sciences and medical degrees from Oxford
University, and a Master’s in Public Health from Harvard
University. He gained membership to the UK Royal College of
Physicians and currently serves as a Board Trustee for Parkinson’s
UK.“With his experience spearheading pipeline and commercial
operations while implementing corporate strategies, I fully support
Andrew’s appointment to CEO as the right step for ITM’s growth. It
has been an honor to guide this organization over the past decade,
and I look forward to contributing to its continued progress,”
commented Steffen Schuster, CEO of
ITM.About ITM Isotope Technologies Munich
SEITM, a leading radiopharmaceutical biotech company, is
dedicated to providing a new generation of radiomolecular precision
therapeutics and diagnostics for hard-to-treat tumors. We aim to
meet the needs of cancer patients, clinicians and our partners
through excellence in development, production and global supply.
With improved patient benefit as the driving principle for all we
do, ITM advances a broad precision oncology pipeline, including two
phase III studies, combining the company’s high-quality
radioisotopes with a range of targeting molecules. By leveraging
our nearly two decades of pioneering radiopharma expertise, central
industry position and established global network, ITM strives to
provide patients with more effective targeted treatment to improve
clinical outcome and quality of life.
www.itm-radiopharma.comITM
ContactCorporate CommunicationsKathleen
Noonan/Julia WestermeirPhone: +49 89 329 8986
1500Email: communications@itm-radiopharma.com
Investor RelationsBen OrzelekPhone: +49 89 329
8986 1009Email: investors@itm-radiopharma.com
- 20240620_ITM_CEO Announcement_Dr. Andrew Cavey_EN
- Portrait Picture_Andrew Cavey (1)
- Portrait Picture_Andrew Cavey (2)